Product Information
PHEXX 1.8-1-0.4% VAGINAL GEL is a brand product labeled by Evofem, Inc., priced at $6.0541 per GM under NDC 69751010112. Its NADAC has been published 40 times since Dec 31, 2025.
FDA first approved this application on May 22, 2020.
PHEXX 1.8-1-0.4% VAGINAL GEL
lactic acid, L-, citric acid monohydrate, and potassium bitartrateStrength
50; 90; 20 mg/5g; mg/5g; mg/5g
Manufacturer
Evofem, Inc.NDC
69751010112
Classification
Brand
Dosage Form
GEL
Route
VAGINAL
Effective Date
9/23/2026
Active Ingredients
CITRIC ACID MONOHYDRATE; LACTIC ACID, L-; POTASSIUM BITARTRATEApproval Type
New Drug (NDA)
FDA Application
NDA208352FDA Approved
5/22/2020
On Market Since
8/1/2020
Pharmacological Classes
Price Statistics
The NADAC for PHEXX 1.8-1-0.4% VAGINAL GEL has been published 40 times since Dec 31, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.0541 per GM |
|---|---|
| All-time high | $6.0706 (May 13, 2026) |
| All-time low | $6.0515 (Jun 17, 2026) |
| 52-week high | $6.0706 |
| 52-week low | $6.0515 |
| Median price | $6.0668 |
| Average price | $6.0628 |
| Largest weekly change | -0.2% (Jun 17, 2026) |
| Weeks tracked | 40 |
| Tracking since | Dec 31, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Evofem, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lactic acid, L-, citric acid monohydrate, and potassium bitartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-coagulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHEXX 1.8-1-0.4% VAGINAL GEL?
The current National Average Drug Acquisition Cost (NADAC) for PHEXX 1.8-1-0.4% VAGINAL GEL, manufactured by Evofem, Inc., is $6.0541 per GM (NDC 69751010112), effective Sep 30, 2026.
How has the price of PHEXX 1.8-1-0.4% VAGINAL GEL changed over time?
Over the history we have for it, the NADAC for PHEXX 1.8-1-0.4% VAGINAL GEL has held within roughly two percent of its current level. It has been tracked across 40 weekly CMS publications since Dec 31, 2025.
What are the highest and lowest recorded NADAC prices for PHEXX 1.8-1-0.4% VAGINAL GEL?
Since Dec 31, 2025, the NADAC for PHEXX 1.8-1-0.4% VAGINAL GEL has ranged from a low of $6.0515 (Jun 17, 2026) to a high of $6.0706 (May 13, 2026), with a median of $6.0668 per GM.
Are there cheaper alternatives to PHEXX 1.8-1-0.4% VAGINAL GEL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PHEXX 1.8-1-0.4% VAGINAL GEL in a comparable dosage form, but none are currently priced below it.
Who manufactures PHEXX 1.8-1-0.4% VAGINAL GEL?
PHEXX 1.8-1-0.4% VAGINAL GEL (NDC 69751010112) is labeled by Evofem, Inc., and CMS classifies it as a brand product.